Search
Now showing items 1-5 of 5
In vitro apoptotic effects of farnesyltransferase blockade in acute myeloid leukemia cells
(2016)
Farnesyltransferase inhibitors (FTIs)
are a class of oral anti-cancer drugs currently tested
in phase I-II clinical trials for treatment of
hematological malignancies. The in vitro effects of
various FTIs (alpha-hydroxyf ...
67 kDa laminin receptor (67LR) in normal and neoplastic hematopoietic cells: is its targeting a feasible approach?
(2016)
The 67 kDa laminin receptor (67LR)
is a non-integrin cell surface receptor for laminin
(LM) that derives from a 37 kDa precursor (37LRP).
67LR expression is increased in neoplastic cells and
correlates with an enhanced ...
Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer
(2016)
The urokinase (uPA)-type
plasminogen activator receptor (uPAR) is a GPIanchored receptor that focuses urokinase (uPA)
proteolytic activity on the cell surface. uPAR also
regulates cell adhesion, migration and proliferati ...
Prolonged complete hematologic response in relapsed/refractory T-large granular lymphocyte leukemia after bendamustine treatment
(2016)
T-large granular lymphocyte
leukemia (T-LGLL) is a chronic clonal proliferation
of effector memory cytotoxic CD3+CD57+CD56- T
cells and the current guidelines suggest
immunosuppressive therapy as first-line therapy, but
the ...
The urokinase/urokinase receptor system in mast cells: effects of its functional interaction with fmlf receptors
(2016)
Mast cell and basophils express the high
affinity receptor for IgE (FcRI) and are primary
effector cells of allergic disorders. The urokinase
(uPA)-mediated plasminogen activation system is
involved in physiological and ...